当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > Association between systemic inflammation and obstructive sleep apnea in men with or at risk for HIV infection.

Association between systemic inflammation and obstructive sleep apnea in men with or at risk for HIV infection.

Abstract：

BACKGROUND:We sought to determine whether markers of systemic inflammation are associated with the presence of moderate/severe obstructive sleep apnea (OSA) and whether this association differs based on HIV and HIV treatment status. METHODS:HIV-uninfected men (HIV-; n=60), HIV-infected men receiving HAART (HIV+/HAART; n=58) and HIV-infected men not receiving HAART (HIV+/no HAART; n=41) underwent polysomnograpy and measurement of plasma levels of tumour necrosis factor (TNF)-α, soluble TNF-α receptors I and II (sTNFRI and sTNFRII) and interleukin (IL)-6. The relationship between moderate/severe OSA (respiratory disturbance index ≥15 apnea/hypopnea events/h) and inflammatory markers was assessed with multivariable regression models. RESULTS:Compared with the HIV- men, HIV+/HAART men and HIV+/no HAART men had higher levels of TNF-α, sTNFRI and sTNFRII, independent of age, race, smoking status, obstructive lung disease (OLD) and body mass index (BMI). Moderate/severe OSA was present in 48% of the sample (HIV- 57%; HIV+/HAART 41%; HIV+/no HAART 44%). Among the HIV+/no HAART men, but not in the other groups, TNF-α, sTNFRII and IL-6 levels were higher in those with moderate/severe OSA compared to men with no/mild OSA after adjustment for age, race, smoking status, OLD and BMI. Within this group, the association of high TNF-α concentrations with moderate/severe OSA was also independent of CD4(+) T-cell count and plasma HIV RNA concentration. CONCLUSIONS:Compared with HIV+/HAART men and HIV- men, markers of systemic inflammation were higher in HIV+/no HAART men. In these men, TNF-α was significantly related to OSA, independent of HIV-related covariates.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Brigham EP,Patil SP,Jacobson LP,Margolick JB,Godfrey R,Johnson J,Johnson-Hill LM,Reynolds S,Schwartz AR,Smith PL,Brown TT

doi

10.3851/IMP2745

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

725-33

issue

8

eissn

1359-6535

issn

2040-2058

journal_volume

19

pub_type

杂志文章,多中心研究

相关文献

ANTIVIRAL THERAPY文献大全
  • Targeting human papillomavirus genome replication for antiviral drug discovery.

    abstract：:Human papillomavirus (HPV) infections are a major human health problem; they are the cause of recurrent benign warts and of several cancers of the anogenital tract and head and neck region. Although there are two prophylactic HPV vaccines that could, if used universally, prevent as many as two-thirds of HPV-induced ca...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2612

    authors： Archambault J,Melendy T

    更新日期：2013-01-01 00:00:00

  • Predicting antiretroviral drug resistance from the latest or the cumulative genotype.

    abstract：BACKGROUND:This study evaluates the added benefit when estimating antiretroviral drug resistance of combining all available resistance test results in a cumulative genotype relative to using the latest genotype alone. METHODS:The prevalence of resistance and genotypic sensitivity scores (GSS) predicted by the latest a...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1753

    authors： Garcia F,Alvarez M,Fox Z,Garcia-Diaz A,Guillot V,Johnson M,Chueca N,Phillips A,Hernández-Quero J,Geretti AM

    更新日期：2011-01-01 00:00:00

  • The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy.

    abstract：BACKGROUND:Drug-resistant HBV mutants frequently arise during nucleoside/nucleotide analogue (NA) therapy, while the resistance mutations on polymerase also have consequent changes in the S protein. The enrichment of immune-escape mutations was negatively correlated with hepatitis B surface antigen (HBsAg) clearance un...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3156

    authors： Shan M,Shen Z,Sun H,Zheng J,Zhang M

    更新日期：2017-01-01 00:00:00

  • Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients.

    abstract：BACKGROUND:In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported. The aim of this study was to investigate the association of IR ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2743

    authors： Degasperi E,Valenti L,Aghemo A,De Francesco R,Rumi M,Soffredini R,Donnici L,Cheroni C,Fargion S,Zanoni V,Orsi E,Colombo M

    更新日期：2014-01-01 00:00:00

  • P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.

    abstract：BACKGROUND:Drug efflux (for example, P-glycoprotein [P-gp], multidrug resistance-associated proteins [MRPs] and breast cancer resistance protein [BCRP]) and influx (for example, human organic anion transporting polypeptide [hOCTP] or human organic anion transporting polypeptide [hOATP]) transporters alter the cellular ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1399

    authors： Janneh O,Anwar T,Jungbauer C,Kopp S,Khoo SH,Back DJ,Chiba P

    更新日期：2009-01-01 00:00:00

  • The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.

    abstract：BACKGROUND:Peripheral neuropathy (PN) in HIV-infected individuals is thought be due to a toxic effect on mitochondria induced by some nucleoside reverse transcriptase inhibitors (NRTI). METHODS:A time-to-event analysis was performed using data from the Delta trial to study the incidence of PN in HIV-infected individua...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：

    authors： Arenas-Pinto A,Bhaskaran K,Dunn D,Weller IV

    更新日期：2008-01-01 00:00:00

  • Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.

    abstract：BACKGROUND:Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1-6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with other HCV PIs. In a 3-day Phase Ib monotherapy study in patients infected ...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.3851/IMP3202

    authors： Lawitz E,Yang JC,Stamm LM,Taylor JG,Cheng G,Brainard DM,Miller MD,Mo H,Dvory-Sobol H

    更新日期：2018-01-01 00:00:00

  • Tenofovir-based antiretroviral therapy in 
HBV-HIV coinfection: results from the TREAT Asia HIV Observational Database.

    abstract：BACKGROUND:The World Health Organization recommends HBV-HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. METHODS:HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observation...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP2972

    authors： Boettiger DC,Kerr S,Ditangco R,Chaiwarith R,Li PC,Merati TP,Pham TT,Kiertiburanakul S,Kumarasamy N,Vonthanak S,Lee CK,Van Kinh N,Pujari S,Wong WW,Kamarulzaman A,Zhang F,Yunihastuti E,Choi JY,Oka S,Ng OT,Kantipong

    更新日期：2016-01-01 00:00:00

  • Antiretroviral therapy in resource-limited settings: is there still a role for stavudine?

    abstract：:Phanuphak et al. compared three strategies for first-line antiretroviral therapy in 150 Thai patients: initiating therapy with zidovudine (AZT), tenofovir disoproxil fumarate (TDF), or a 24-week lead-in phase with stavudine (d4T) followed by a switch to AZT. Those taking d4T had higher haemoglobin levels and CD4(+) T-...

    journal_title：Antiviral therapy

    pub_type： 评论,杂志文章

    doi：10.3851/IMP2498

    authors： Gallant JE

    更新日期：2012-01-01 00:00:00

  • Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.

    abstract：OBJECTIVE:The lipodystrophy syndrome is a major adverse effect of highly active antiretroviral therapy (HAART), associated with altered circulating levels and adipose tissue mRNA expression of proinflammatory cytokines interleukin-6 (IL-6) and tumour necrosis factor (TNF)alpha, and adiponectin. Proinflammatory cytokine...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Lagathu C,Bastard JP,Auclair M,Maachi M,Kornprobst M,Capeau J,Caron M

    更新日期：2004-12-01 00:00:00

  • Infrequent transmission of HIV-1 drug-resistant variants.

    abstract：:Transmission of drug-resistant variants is influenced by several factors, including the prevalence of drug resistance in the population of HIV-1-infected patients, HIV-1 RNA levels and transmission by recently infected patients. In order to evaluate the impact of these factors on the transmission of drug-resistant var...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Yerly S,Jost S,Telenti A,Flepp M,Kaiser L,Chave JP,Vernazza P,Battegay M,Furrer H,Chanzy B,Burgisser P,Rickenbach M,Gebhardt M,Bernard MC,Perneger T,Hirschel B,Perrin L,Swiss HIV Cohort Study.

    更新日期：2004-06-01 00:00:00

  • Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels.

    abstract：BACKGROUND:Quantification of HBsAg in serum may be of clinical importance in predicting HBsAg seroconversion and complete response to treatment. METHODS:Serum HBsAg was quantified by ADVIA Centaur in 63 patients with HBeAg-negative chronic hepatitis B (CHBe-). A total of 42 had received interferon-alpha2b (IFN-alpha2b...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Manesis EK,Hadziyannis ES,Angelopoulou OP,Hadziyannis SJ

    更新日期：2007-01-01 00:00:00

  • Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.

    abstract：BACKGROUND:Little is known about the efficacy, safety and tolerability of pegylated interferon plus ribavirin treatment in patients with chronic hepatitis Cvirus (HCV) infection and histologically proven fully established cirrhosis. We aimed here to evaluate the safety of this regimen in such patients and to identify b...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：

    authors： Roffi L,Colloredo G,Pioltelli P,Bellati G,Pozzpi M,Parravicini P,Bellia V,Del Poggio P,Fornaciari G,Ceriani R,Ramella G,Corradi C,Rossini A,Bruno S,Gruppo Epatologico Lombardo.

    更新日期：2008-01-01 00:00:00

  • Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.

    abstract：OBJECTIVE:The aim of the study was to analyse the response to highly active antiretroviral therapy (HAART) initiated at the time of primary HIV infection (PHI) in patients infected with a virus resistant to > or = 1 drug of their treatment compared with patients infected with a wild-type virus. METHODS:We analysed dat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Chaix ML,Desquilbet L,Descamps D,Costagliola D,Deveau C,Galimand J,Goujard C,Signori-Schmuck A,Schneider V,Tamalet C,Pellegrin I,Wirden M,Masquelier B,Brun-Vezinet F,Rouzioux C,Meyer L,French PRIMO Cohort Study Group (ANR

    更新日期：2007-01-01 00:00:00

  • Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia.

    abstract：:A 14 year old common variable immunodeficiency patient developed severe protein-losing enteropathy. A chronic enteral infection with human parechovirus type 1 and norovirus was diagnosed. Treatment strategies aimed at virus eradication and providing supportive care were ineffective. The antipicornavirus agent pleconar...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1792

    authors： van de Ven AA,Douma JW,Rademaker C,van Loon AM,Wensing AM,Boelens JJ,Sanders EA,van Montfrans JM

    更新日期：2011-01-01 00:00:00

  • Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.

    abstract：BACKGROUND:This study aimed to examine the evolution of genotypic drug resistance prevalence in treatment-failing patients in the multicentre, Italian, Antiretroviral Resistance Cohort Analysis (ARCA). METHODS:Patients with a drug resistance genotype test performed between 1999 and 2006 at failure of a combination ant...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Di Giambenedetto S,Zazzi M,Corsi P,Gonnelli A,Di Pietro M,Giacometti A,Almi P,Trezzi M,Boeri E,Gianotti N,Menzo S,Del Gobbo R,Francisci D,Nerli A,Galli L,De Luca A,Antiretroviral Resistance Cohort Analysis Study Group.

    更新日期：2009-01-01 00:00:00

  • Antiviral activity of FNC, 2'-deoxy-2'-β-fluoro-4'-azidocytidine, against human and duck HBV replication.

    abstract：BACKGROUND:New drugs are needed to combat HBV infection. We investigated the anti-HBV activity of the deoxycytidine analogue FNC, which has anticancer activity and has been found to inhibit HCV replication. METHODS:In this study, a human hepatoma HepG2.2.15 cell culture system and duck HBV (DHBV) infection model were ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2094

    authors： Zheng L,Wang Q,Yang X,Guo X,Chen L,Tao L,Dong L,Li Y,An H,Yu X,Wang Q,Chang J

    更新日期：2012-01-01 00:00:00

  • Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy.

    abstract：BACKGROUND:Little is known about the prognostic factors of acute liver enzyme variations in HIV-hepatitis B virus (HBV)-coinfected patients. OBJECTIVES:To identify prognostic factors of acute liver enzyme abnormalities in HIV-HBV-coinfected patients with a focus on the putative role of antiretroviral drugs. DESIGN:Da...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Chauvel O,Lacombe K,Bonnard P,Lascoux-Combe C,Molina JM,Miailhes P,Girard PM,Carrat F

    更新日期：2007-01-01 00:00:00

  • Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.

    abstract：BACKGROUND:Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS:Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Vogel M,Nattermann J,Baumgarten A,Klausen G,Bieniek B,Schewe K,Jessen H,Boesecke C,Rausch M,Lutz T,Fenske S,Schranzo D,Kümmerle T,Schuler C,Theisen A,Mayr C,Seidel T,Rockstroh JK

    更新日期：2006-01-01 00:00:00

  • Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.

    abstract：OBJECTIVES:To characterize 1-year virological response to antiretroviral therapy and its determinants by sex. METHODS:This is a population-based analysis of antiretroviral therapy naive HIV-positive adult men and women. Factors associated with sex and with plasma HIV RNA viral load suppression to below 500 copies/ml w...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： O'Connell JM,Braitstein P,Hogg RS,Yip B,Craib KJ,O'Shaughnessy MV,Montaner JS,Burdge DR

    更新日期：2003-12-01 00:00:00

  • A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.

    abstract：:Although zidovudine (ZDV) is effective in HIV-1-infected patients, the duration of its efficacy may be short when treatment is started in advanced HIV disease. This pilot prospective case-control study was designed to evaluate the combination of ZDV plus didanosine [ddI] compared with ZDV monotherapy as an initial the...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Gatell JM,Leal M,Mallolas J,Vidal C,Pumarola T,Parra R,Padró S,Caruz A,Falgueras T,Rey C,Sánchez-Quijano A,Torres Y,Lissen E,Jiménez de Anta MT,Soriano E

    更新日期：1996-04-01 00:00:00

  • Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.

    abstract：BACKGROUND:We examined whether waist circumference (WC) and self-reported abdominal size changes can estimate visceral adipose tissue (VAT) changes for those initiating antiretroviral therapy (ART). METHODS:Prospectively collected data from ACTG A5257 and its metabolic substudy, A5260s, were used for this analysis. AR...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3148

    authors： Bhagwat P,Ofotokun I,McComsey GA,Brown TT,Moser C,Sugar CA,Currier JS

    更新日期：2017-01-01 00:00:00

  • 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.

    abstract：BACKGROUND:Few data are available about efficacy and durability of simplification from multi-tablet antiretroviral regimens to co-formulated efavirenz (EFV)/emtricitabine (FTC)/tenofovir (TDF) versus rilpivirine (RPV)/FTC/TDF in virologically suppressed HIV-1-infected patients. METHODS:We retrospectively analysed HIV-...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP3188

    authors： Gagliardini R,Bandera A,Zaccarelli M,Sterrantino G,Latini A,D'Avino A,Lapadula G,Antinori A,Cauda R,De Luca A,Gori A,Di Giambenedetto S,Fabbiani M

    更新日期：2018-01-01 00:00:00

  • Cidofovir does not prevent caprine herpesvirus type-1 neural latency in goats.

    abstract：BACKGROUND:Cidofovir (CDV) is an acyclic nucleoside phosphonate that exhibits a potent antiviral activity against several DNA viruses. In previous studies, CDV has been shown to significantly reduce the clinical severity and the viral shedding in primary caprine herpesvirus type-1 (CpHV-1) infection in goats. CpHV-1 is...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1611

    authors： Camero M,Crescenzo G,Marinaro M,Tarsitano E,Bellacicco AL,Armenise C,Buonavoglia C,Tempesta M

    更新日期：2010-01-01 00:00:00

  • Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.

    abstract：:The aim of this study (the RESCUE trial) was to verify the effect of a shift from a lamivudine-containing to a didanosine-containing regimen on viral replication in HIV-1-infected subjects who had experienced prior treatment failure. Sixteen patients (didanosine-experienced in 14/16 cases) were consecutively enrolled:...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Rusconi S,La Seta Catamancio S,Citterio P,Bulgheroni E,Kurtagic S,Galazzi M,Croce F,Moroni M,Galli M

    更新日期：2001-03-01 00:00:00

  • Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.

    abstract：:Cytomegalovirus (CMV) remains a leading cause of morbidity after solid organ transplantation. The efficiency of antivirals for the treatment of CMV infections may be hampered because of the emergence of CMV resistance to antivirals. The development of CMV multidrug resistance, which remains uncommon but does occur, co...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2818

    authors： Deback C,Burrel S,Varnous S,Carcelain G,Conan F,Aït-Arkoub Z,Autran B,Gandjbakhch I,Agut H,Boutolleau D

    更新日期：2015-01-01 00:00:00

  • Smoking motivations and quitting motivations among HIV-infected smokers.

    abstract：BACKGROUND:The aim of this study was to examine smoking motivation and motivation to quit, and determinants of these motivations among HIV-infected cigarette smokers. METHODS:We conducted a 1-day cross-sectional survey on cigarette smoking in a representative sample of HIV-infected outpatients of French hospitals. A c...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1292

    authors： Peretti-Watel P,Garelik D,Baron G,Spire B,Ravaud P,Duval X,EVIT Study Group.

    更新日期：2009-01-01 00:00:00

  • Is there a need for liver disease monitoring in HIV patients in Africa?

    abstract：:Liver disease is one of the leading causes of death in HIV-infected individuals from Europe and North America and has been attributed mainly to coinfection with hepatotropic viruses. Little data, however, has so far become available on liver disease in HIV-infected individuals from Africa. Results from a first study o...

    journal_title：Antiviral therapy

    pub_type： 评论,杂志文章

    doi：10.3851/IMP1787

    authors： Rockstroh JK,Peters L,Wedemeyer H

    更新日期：2011-01-01 00:00:00

  • Successful treatment of rapidly progressing severe fever with thrombocytopenia syndrome with neurological complications using intravenous immunoglobulin and corticosteroid.

    abstract：:Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in China, diagnostic methods have evolved. Despite definitive diagnoses, SFTS management has focused on prevention and supportive care. Although conservative treatment is effective for mild cases, there is an urgent need for an effective ther...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3036

    authors： Kim UJ,Kim DM,Ahn JH,Kang SJ,Jang HC,Park KH,Jung SI

    更新日期：2016-01-01 00:00:00

  • Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.

    abstract：BACKGROUND:IL28B genotype predicts response to treatment against HCV with pegylated interferon/ribavirin (PR) and impacts on the outcome of therapy including telaprevir (TVR). This study aimed to determine the influence of the favourable IL28B genotype on early viral kinetics during therapy with TVR/PR in HIV-HCV-coinf...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP2921

    authors： Neukam K,Munteanu D,Haubitz S,Mira JA,Ingiliz P,Rivero-Juárez A,Lutz T,de los Santos-Gil I,Scholten S,Márquez M,Rauch A,Rockstroh JK,Pineda JA

    更新日期：2015-01-01 00:00:00